Duchenne Muscular Dystrophy Clinical Trial
— DIGDOfficial title:
Digestive Events in Duchenne Muscular Dystrophy Patients
NCT number | NCT04384354 |
Other study ID # | DIGDMD |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 2007 |
Est. completion date | April 2019 |
Verified date | May 2020 |
Source | Centre d'Investigation Clinique et Technologique 805 |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Relation between clinical and genetic features and acute digestive events in Duchenne muscular dystrophy patients
Status | Completed |
Enrollment | 200 |
Est. completion date | April 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | |
Gender | Male |
Age group | 15 Years and older |
Eligibility |
Inclusion Criteria: - all Duchenne muscular dystrophy patients in our center Exclusion Criteria: - none |
Country | Name | City | State |
---|---|---|---|
France | CICIT805 | Garches |
Lead Sponsor | Collaborator |
---|---|
Centre d'Investigation Clinique et Technologique 805 |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of digestive events | Clinical parameters (yes or no): gastrostomy, bowel occlusion, acute gastric paresia, biliary complication | 11 years | |
Primary | Prevalence of digestive events | Clinical parameters (yes or no) : gastrostomy, bowel occlusion, acute gastric paresia, biliary complication | 11 years | |
Primary | Risk factors for digestive events (1) | age (years) | 11 years | |
Primary | Risk factors for digestive events (2) | pulmonary functional tests (vital capacity in ml/kg) | 11 years | |
Primary | Risk factors for digestive events (3) | echocardiography parameters (LVEF: left ventricular ejection fraction in %) | 11 years | |
Primary | Risk factors for digestive events (4) | residual dystrophin level (Western blot and/or immunohistochemistry in muscle) | 11 years | |
Primary | Risks factors for digestive events (5) | genetic parameters (type of mutation, functional domain of altered dystrophin) | 11 years | |
Secondary | Nutritional status (1) | Weigh (kg) and height (in m) agregated in BMI (kg/m^2) | 11 years | |
Secondary | Nutritional status (2) | albuminemia in g/L | 11 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05575648 -
Dual Task in Duchenne Muscular Dystrophy
|
N/A | |
Terminated |
NCT03907072 -
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450639 -
An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Active, not recruiting |
NCT04906460 -
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02500381 -
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 3 | |
Enrolling by invitation |
NCT05967351 -
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
|
Phase 3 | |
Recruiting |
NCT03067831 -
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT01834040 -
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT02246478 -
A Study of TAS-205 for Duchenne Muscular Dystrophy
|
Phase 1 | |
Active, not recruiting |
NCT01772043 -
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
|
N/A | |
Terminated |
NCT01168908 -
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT00758225 -
Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)
|
Phase 2 | |
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Recruiting |
NCT03513367 -
The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
|
||
Recruiting |
NCT05712447 -
Duchenne Muscular Dystrophy Video Assessment Registry
|
||
Recruiting |
NCT01484678 -
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|
||
Completed |
NCT03319030 -
Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
|
||
Terminated |
NCT01753804 -
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
|
N/A | |
Completed |
NCT02530905 -
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
|
Phase 1 |